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S258 Poster Session Imulti-potent on the other, in experimental autoimmune encephalitis
(EAE), and found that treatment of mice with bone marrow derived
MSCs resulted in significant suppression of anti-self reactivity and
improved clinical and pathological disease manifestations. Using
green fluorescent donors, we documented that in addition to down
regulation of autoimmunity, neural differentiation of these cells
may occur in vivo. These observations suggested that treatment
with MSCs might be used for immune regulation and neuroprotec-
tion for patients with MS. Our preliminary results of a phase I/II
open clinical trial to evaluate the feasibility and safety of intrathecal
and intravenous administration of autologous bone marrow derived
MSCs in patients with severe MS failing conventional modalities
suggested that treatment with MSCs is feasible, safe and potentially
effective. No major side effect were developed or reported during
a follow up period of nearly 4 years. Based on our successful prelim-
inary pilot study in 13 patients with MS and 14 with ALS, a total of
.150 patients were treated with autologous bone marrow derived
MSCs, mostly.100 patients withMS alone were treated at our cen-
ter with MSCs administered partially intrathecally (106 MSC/Kg)
and additional 5 - 10x105/Kg intravenously. The treatment was un-
eventful with headache due to lumbar puncture being the most fre-
quent complaint (70%) and self-limited subfebrile temperature in
25% and no serious side effect. A total of 60 % of patients reported
improved outcome, in some with very significant objective improve-
ment of disease manifestations with subjective and objective im-
provement of EDSS score. More recently, we have discovered
a new proprietary technology which allows differentiation of both
bone marrow, adipose tissue derived and cord/placenta derived
MSCs into neural stem cells, motor neurons, dopaminergic neurons,
astrocytes and myelin basic protein secreting oligodendrocytes that
in principle may be used to induce remyelination. These results sug-
gest that treatment with MSCs may provide the most suitable ap-
proach for treatment of MS, which could also be applicable for
treatment of other neurodegenerative disorders.146
AVOIDING THE NEED FOR CLINICAL-GRADE OKT3: EX VIVO EXPANSION
OF T CELLS USING ARTIFICIAL ANTIGEN PRESENTING CELLS GENETI-
CALLY MODIFIED TO CROSS-LINK CD3
Ang, S.O., Maiti, S.N., Hartline, C., Olivares, S., Huls, H.,
Champlin, R., Cooper, L.J.N. University of Texas MD Anderson Cancer
Center
T-cell immunotherapy protocols rely on activation for sustained
proliferation in the ex vivo expansion of T cells to achieve clinically
meaningful numbers for human applications. We have successfully
expanded T cells using a robust platform technology based on
K562 cells genetically modified to function as artificial antigen pre-
senting cells (aAPC) for the numeric expansion of T cells. An aAPC
clone (clone #4) was engineered to have enforced co-expression of
CD64, CD86, membrane-bound interleukin (IL)-15, and CD137L
(41BBL). Mouse anti-human CD3 (OKT3) monoclonal antibody
can be loaded (bound by CD64) onto the aAPC to cross-link CD3
triggering ex vivo T-cell propagation. However, as clinical-grade
Orthoclone OKT3 (muromonab from Ortho Biotech) is no longer
available we generated a genetic approach to avoid the need to
load OKT3. This was accomplished by heterologous fusion of the
scFv region from OKT3 mAb to a drug resistance gene cassette
(C3hygro) and enforcing expression under selection with hygromycin
B.We initially expressed the C3hygro on tumor cells (e.g.,MB-MDA-
231 breast cancer cell line) and demonstrated with time-lapse video
microscopy that C3hygro+ tumor cells could be efficiently killed by
primary humanT cells. This is similar in principle to the mechanism
of action for bi-specific antibodies whereby T cells are brought into
contact with antigen+ tumor cells, as our C3hygro+ tumor cells can be
killed by previously unmodified T cells. We then adapted aAPC
clone 4 to express C3hygro to generate a cellular platform for the
non-specific propagation of T cells. These aAPC (K562OKT3) co-ex-
press the recognition domain of OKT3 in addition to the desired T-
cell co-stimulatory molecules. T cells propagated using g-irradiated
K562OKT3 aAPC similar to OKT3-loaded clone #4 aAPC have com-
parable phenotype by flow cytometric analysis. The use of K562 is
clinically appealing as we have generated master cell banks underINDs based on this cell line functioning as aAPC for human applica-
tion. Indeed, the development of K562OKT3 aAPC appears to be
a useful substitute for clinical protocols dependent on clinical-grade
OKT3. In summary, we report our recent efforts to generateOKT3-
based reagents K562OKT3 and C3hygro, useful for both clinical and
research applications.147
CO-TRANSPLANTATION OF POOLED CORD BLOOD (CB) THIRD-PARTY
UNIT, HLA-BLIND, CD34+ SELECTED CBU WITH A SINGLE 4-6/6 HLA-
COMPATIBLE CBU FOR ALLOGENEIC SCT IMPROVES ENGRAFTMENT
TIME
Peltier, L., Monczak, Y., Laneuville, P. McGill University, Montreal,
QC, Canada
Finding an HLA-compatible cord blood unit (CBU) containing
sufficient cells to ensure engraftment remains a significant obstacle
to the widespread adoption of cord blood grafts for allogeneic stem
cell transplantation in adults. This limitation can be overcome, as is
current practice, by co-transplanting two or three HLA-compatible
CBUs. This approach however is associated with increased graft pro-
curement expenses, and reduced probability of findingmore than one
compatible cord blood unit (CBU). Other approaches in develop-
ment include in vitro expansion and intraosseous infusion. We have
developed an alternative approach with the aim of increasing graft
cell content by creating third-party support fromCBUs that are con-
sidered to be too small for banking and that are normally discarded.
We prospectively collected these smaller CBUs and then developed
a rapid thawing method allowing the pooling of CBUs blinded to
HLA followed by CD34+ selection, to create a third-party graft for
allogeneic stem cell transplantation in adults. We report the results
on the first four high risk patients transplanted in a phase I/II trial
at our institution where the primary endpoint is time to engraftment.
All four patients received a 4/6 or 5/6HLAcompatibleCBUcontain-
ing 2.5 to 2.9 x10e7NC/Kg followedwithin2hours by the infusionof
the third-party graft after Flu-BuCy2 conditioning. All patients had
100% matched CBU chimerism at day +14 and the mean nucleated
cells (NC) engraftment was 19.7 days. Three patients were alive at
day +100 and one patient died at day +28 of acute relapse.
Table. Engraftment Time of the Match CBU
CD34 CD34Pt # DiagnosisAge
(Sexe)Weight
(Kg)HLA
Match(x10e5/kg)
Matched
CBU(x10e5/kg)
Third-Party
CBUsNC $0.5 
10e9/L1 NHL 41 (M) 81 4/6 1.1 3.0 D +152 CML 30 (M) 56 5/6 0.67 2.0 D +263 AML 32 (F) 88 4/6 1.63 2.5 D +184 ALL 57 (F) 72 5/6 1.3 1.9 D +21These results demonstrate that increasing the number ofHSC to sup-
port a$ 4/6HLA compatible CBU using third-party cells from pooled
HLAblindCBUs is safe, feasible, and results in rapid engraftment com-
pared to single CBU transplants. The advantage of this approach is that
it may be possible to obtain engraftment times comparable to multi-
matched CBU transplants, without having to find more than one com-
patible CBU, while salvaging otherwise discarded CBUs.148
CD8aa+ T CELLS, A NEW MEMORY T CELL COMPARTMENT
Magalhaes, I.1, Maeurer, M.J.1,2 1Karolinska Institutet, Stockholm, Swe-
den; 2Karolinska Institutet, Stockholm, Sweden
Adoptive T cell therapy is based on the genetic introduction of T
cell receptor (TCR) a- and b-chains to redirect effector T cell spec-
ificity. This is a well-established approach to generate ex vivo large
amounts of effector cells with defined specificity. The adoptive trans-
fer of high affinity CMV- and EBV- specific MHC-I restricted
